Invited debate: NHS Health Checks - A naked emperor?

Journal of Public Health (United Kingdom)

Volumn 37, Issue 2, 2015, Pages 187-192

  Capewell, Simon ^a   McCartney, Margaret ^b   Holland, Walter ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b London School of Economics ^*  (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CARDIOVASCULAR DISEASES; ENGLAND; FEMALE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; MALE; MASS COMMUNICATION; MASS SCREENING; MIDDLE AGED; NATIONAL HEALTH SERVICE; ORGANIZATION AND MANAGEMENT; POLITICS; PROGRAM EVALUATION; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; RISK ASSESSMENT;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIFFUSION OF INNOVATION; ENGLAND; FEMALE; HEALTH POLICY; HEALTH PRIORITIES; HEALTH PROMOTION; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; POLITICS; PROGRAM EVALUATION; PUBLIC HEALTH PRACTICE; QUALITY INDICATORS, HEALTH CARE; QUALITY OF HEALTH CARE; RISK ASSESSMENT; STATE MEDICINE;

EID: 84930703566     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fdv063     Document Type: Review

References (56)

1. NHS Health Checks. Public Health England. http://www. healthcheck.nhs.uk/ (21 April 2015, date last accessed).
2. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. WHO Chronicle Geneva: World Health Organization. Public Health Papers, #34, 1968, 22(11), 473 p. http://www.nature. com/gim/journal/v15/n3/fig-tab/gim2012176t1.html (11 May 2015, date last accessed)
3. McCartney M. Where's the evidence for NHS health checks? BMJ 2013;347:f5834.
4. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment. Lancet Diabetes Endocrinol 2014;2(8):634-47. Epub 2014 May 16.
5. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: A prospective open cohort study. BMJ 2009;339:b2584.
6. Jackson R, Marshall R, Kerr A et al. QRISK or Framingham for predicting cardiovascular risk? BMJ 2009;339:b2673.
7. Public Health Outcomes Framework. http://www.phoutcomes.info/ public-health-outcomes-framework#gid/1000042/pat/6/ati/102/page/ 0/par/E12000002/are/E08000012 (21 April 2015, date last accessed).
8. McCartney M. NHS Health Check betrays the ethos of public health. BMJ 2014;349:g4752.
9. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C et al. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev 2012;10:CD009009.
10. Jørgensen T, Jacobsen RK, Toft U et al. Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ 2014;348:g3617.
11. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ et al. Screening for type 2 diabetes and population mortality over 10 years (addition-Cambridge): A cluster-randomised controlled trial. Lancet 2012;380:1741-8.
12. Public Health England. NHS health check: our approach to the evidence, 2013. www.gov.uk/government/uploads/system/uploads/ attachment-data/file/224537/NHS-Health-Check-our-approach-to-the-evidence-v2.pdf (21 April 2015, date last accessed).
13. Booth HP, Prevost TA, Wright AJ et al. Effectiveness of behavioural weight loss interventions delivered in a primary care setting: A systematic review and meta-analysis. Fam Pract 2014;31:6. http://fampra. oxfordjournals.org/content/early/2014/10/08/fampra.cmu064.long (11 May 2015, date last accessed).
14. Heath GW, Parra DC, Sarmiento OL et al. Evidence-based intervention in physical activity: lessons from around the world. Lancet 2012;380 (9838):272-81. http://www.ncbi.nlm.nih.gov/pubmed/22818939 (11 May 2015, date last accessed).
15. Royal College of Physicians of London. Fifty Years Since Smoking and Health. https://www.rcplondon.ac.uk/resources/fifty-yearssmoking-and-health (21 April 2015, date last accessed).
16. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: A new preventive strategy. Health Technol Assess 2003;7(31).
17. Diao D, Wright JM, Cundiff DK et al. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev 2012;8:CD006742.
18. Ray KK, Seshasai SR, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention. A meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med 2010; 170(12):1024-31.
19. Abramson JD, Rosenberg HG, Jewell N et al. Should people at low risk of cardiovascular disease take a statin? BMJ 2013;347:f6123.
20. Bang CN, Okin PM. Statin treatment, new-onset diabetes, and other adverse effects: A systematic review. Curr Cardiol Rep 2014;16(3):461.
21. CurrieO, ManginD,Williman J et al. The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: A national cohort study. BMJ Open 2013;3:e003475.
22. Bell DSH, DiNicolantonio JJ, O'Keefe JH. Is statin-induced diabetes clinically relevant? A comprehensive review of the literature. Diabetes Obes Metab 2014;16(8):689-94.
23. Davidson MH, Sun SX, Nag SS et al. Risk factors for discontinuation of statin medications: evidence from a large National Pharmacy Claims database. Circulation 2007;116:II847.
24. Lewey J, Shrank WH, Bowry AD et al. Gender and racial disparities in adherence to statin therapy: A meta-analysis. Am Heart J 2013;165:665-678.e1.
25. Hawkes N. Two papers in the BMJ with statin side effect errors shouldn't be retracted, independent panel concludes. BMJ 2014;349:g4993.
26. Department of Health. Putting Prevention First. Vascular Checks Risk Assessment and Management Impact Assessment. London: DH, 2008. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH-090351 (11 May 2015, date last accessed).
27. Public Health England Annual Report and Accounts 2013/14. https://www.gov.uk/government/uploads/system/uploads/attachment- data/file/325522/PHE-Annual-Report-and-Accounts-2013-to-2014. pdf (21 April 2015, date last accessed).
28. Guzman Castillo M, Gillespie D, Allen K et al. Future declines of Coronary Heart Disease mortality in England and Wales could counter the burden of population ageing. BMJ Open 2015;5:e006070.
29. NICE. Lipid Modification 2014. www.nice.org.uk/nicemedia/live/ 13637/66549/66549.pdf (21 April 2015, date last accessed).
30. McPherson K. NICE on statins: concerns about the latest NICE draft guidance on statins. BMJ 2014;349:g4130.
31. Harcombe Z. NICE Has Ended Any Debate About Its Independence. 2014. http://www.zoeharcombe.com/2014/07/nice-has-ended-anydebate-about-its-independence/ (21 April 2015, date last accessed).
32. Ungoed-Thomas J. Statins expert 'failed to declare' drugs firm link. Sunday Times, 12 October 2014. http://www.thesundaytimes.co.uk/ sto/news/uk-news/Health/article1470266.ece (11 May 2015, date last accessed).
33. National Institute for Health and Clinical Excellence. Matrix. Economic Analysis of Interventions to Improve the Use of Statins Interventions in the General Population 08 May 2008. https://www.nice.org.uk/ guidance/ph15/evidence/ph15-identifying-and-supporting-peoplemost-at-risk-of-dying-prematurely-supporting-evidence4 (21 April 2015, date last accessed).
34. Mitchell AP, Simpson RJ. Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States. BMC Res Notes 2012;5:373.
35. The South-East London Screening Study GroupHolland WW, Creese AL et al. A controlled trial of multiphasic screening in middle-age: results of the South-East London Screening Study. Int J Epidemiol 1977;6(4):357-63.
36. Neumann P, Cohen J. NEJM Perspective on " The Cost-Effectiveness of Environmental Approaches to Disease Prevention" The CEA Registry Blog. Julby CEA Registry Team 7/26/2012. https://research.tufts-nemc. org/cear4/Resources/CEARegistryBlog/tabid/69/EntryId/246/NEJMPerspective-on-The-Cost-Effectiveness-of-Environmental-Approachesto-Disease-Prevention.aspx (21 April 2015, date last accessed).
37. Report of the Secretary-General A/64/665. Keeping the Promise-A Forward-Looking Review to Promote an Agreed Action Agenda to Achieve the Millennium Development Goals by 2015. http://www. preventionweb.net/english/professional/publications/v.php?id=13841 (21 April 2015, date last accessed).
38. Sugiyama T, Tsugawa Y, Tseng C-H et al. Different time trends of caloric and fat intake between statin users and nonusers among US adults gluttony in the time of statins? JAMA Intern Med 2014;174(7):1038-45.
39. Moynihan R, Heath I, Henry D. Commentary: medicalisation of risk factors-selling sickness, the pharmaceutical industry and disease mongering. BMJ 2002;324:886.
40. Armitage J, Baigent C, Collins R. Misrepresentation of statin safety evidence. Lancet 2014;384(9950):1263-4.
41. Wright O. Revealed: Big Pharma's hidden links to NHS policy, with senior MPs saying medical industry uses 'wealth to influence government'. Independent, 11 Feb 2014. http://www.independent.co.uk/ news/uk/politics/revealed-big-pharma-links-to-nhs-policy-with-seniormps-saying-medical-industry-uses-wealth-to-influence-government-9120187.html (11 May 2015, date last accessed).
42. Harcombe Z. It's Not About Statins-It's About Censorship. Blog, May 19, 2014. http://www.zoeharcombe.com/2014/05/its-not-aboutstatins-its-about-censorship/ (11 May 2015, date last accessed).
43. Khomami N. Welcome to the Coca-Cola London Eye. but health charities are already seeing red. The Observer, Sunday 18 January 2015. http://www.theguardian.com/business/2015/jan/18/coca-colalondon-eye-charity-anger (11 May 2015, date last accessed).
44. Moodie R, Stuckler D, Monteiro C et al. Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet 2013;381(9867):670-9.
45. Stuckler D, Nestle M. Big food, food systems, and global health. PLoS Med 2012;9(6):e1001242.
46. Bonita R, Magnusson R, Bovet P et al. Country actions to meet UN commitments on NCDs: A stepwise approach. Lancet 2013;381(9866): 575-84.
47. Capewell S. BMJ head to head. Will screening individuals at high risk of cardiovascular events deliver large benefits? BMJ 2008;337:a1395.
48. Capewell S, Graham H. Will cardiovascular disease prevention widen health inequalities? PLoS Med 2010;7(8):e1000320.
49. NICE. Prevention of Cardiovascular Disease. Public Health Guidance 25, 2010. www.nice.org.uk/nicemedia/live/13024/49273/49273.pdf (21 April 2015, date last accessed).
50. Barton P, Andronis L, Briggs A et al. Effectiveness and costeffectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ 2011;343:d4044.
51. Vos T, Carter R, Barendregt J et al. Assessing Cost-Effectiveness in Prevention (ACE-Prevention): Final Report. University of Queensland, Brisbane and Deakin University, Melbourne.
52. Mozaffarian D, Capewell S. United Nations dietary policies to prevent cardiovascular disease. Modest diet changes could halve the global burden. BMJ 2011;343:d5747.
53. O'Flaherty M, Flores-Mateo G, Nnoaham K et al. Estimating potential cardiovascular mortality reductions with different food policy options in the UK. WHO Bull 2012;90:522-31.
54. Scholes S, Bajekal M, Norman P et al. Quantifying policy options for reducing future coronary heart disease mortality in England: A modelling study. PLoS One 2013;8(7):e69935.
55. International Evaluation Group. Report of the international evaluation of the National Institute for Health and Welfare. http://www. stm.fi/c/document-library/get-file?folderId=9882185&name=DLFE-30827.pdf (21 April 2015, date last accessed).
56. Conceiçaõ C, Leandro A, McCarthy M. National support to public health research: A survey of European ministries. BMC Public Health 2009;9:203.